Delcath Systems (DCTH) Announces Revised NICE Guidance for CHEMOSAT in the United Kingdom
- Wall Street extends rally, but sets course for weekly loss
- Disney (DIS) Dips As Streaming Business Shows Signs of Slowing Down, Analysts 'Very Bullish' on LT Opportunity
- Airbnb (ABNB) Bookings Up 52% to Help Sales Beat, Seen as a 'Blow Out Quarter' as More Upside is Left
- DoorDash (DASH) Reports Bigger Loss and a Sales Beat, Shares Soars on Strong Guidance and Two Upgrades to 'Buy'
- Coinbase (COIN) To Add Dogecoin Trading in the Next Few Weeks
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE), through the Interventional Procedures Advisory Committee, has updated its guidance for the Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) in the treatment of patients with metastases in the liver from Ocular Melanoma.
Previously, the NICE guidance recommended CHEMOSAT only be used in the context of formal research studies. Due to that guidance, both private insurance and regional funding were generally not available for treatments with CHEMOSAT, nor was it possible to apply for national coverage. Under the revised NICE guidance, CHEMOSAT has been categorized under a Special Arrangement designation. Under this designation, private insurance may be more likely to fund treatment with CHEMOSAT, some regional funding may be more accessible, and a process is now available to seek national reimbursement.
The revised guidance which formed the basis in the designation change can be found at https://www.nice.org.uk/guidance/ipg691.
“We welcome this Special Arrangements designation from NICE for the treatment of patients with metastases in the liver from ocular melanoma and the recommendations within the final guidance. We look forward to working with specialist treatment centers to increase the availability of this treatment to patients with metastases in the liver from ocular melanoma in the UK” said Gerard Michel, CEO of Delcath. “This change in designation, combined with the recently announced positive preliminary results from the FOCUS trial, is further evidence of the potential value of the HEPZATO and CHEMOSAT platform to patients worldwide suffering from metastatic ocular melanoma.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BridgeBio Pharma (BBIO) Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia
- Strongbridge Biopharma (SBBP) Announces FDA Filing Acceptance of NDA for RECORLEV for Treatment of Endogenous Cushing’s Syndrome
- Protalix BioTherapeutics (PLX) Tops Q1 EPS by 3c, Revenues Beat
Create E-mail Alert Related CategoriesCorporate News, FDA
Related EntitiesAdCom, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!